Experts re-rate pharma stocks post weak Q1 show

The once heavyweight pharma darlings of investors and brokerage houses seem to be faltering as pricing pressure in the US markets is building up, and lack of new launches is threatening the future of companies like Sun, Lupin and Cipla. After the first-quarter earnings, the once bullish analysts are re-rating stocks of Dr Reddy’s, Lupin and Cipla. Divya Rajagopal tells you whyhy.